Tagged with P

LatAm Fernando Almeida, EVP China & International Markets, discusses his global pharma career and Chiesi’s evolution into a high-performing, innovation-led group. He highlights strong double-digit growth, disciplined investment, and expansion across China and Latin America, underpinned by access-driven strategies, talent mobility, and long-term patient impact.   To become a strong and…

LatAm From cancer treatments to cardiovascular drugs, access to innovative medicines in South America lags behind developed market norms with patients forced to endure considerable delays for therapies that are already considered global standards. According to the Waiting to Access Innovative Therapies (W.A.I.T.) Indicator from FIFARMA, an association representing research-based pharma…

France Raymond Le Moign leads one of Europe’s largest university hospital centres at a moment when healthcare systems are being forced to rethink how they organise care, innovation, and accountability. Drawing on experience that spans national health policy, oncology, regulation, and frontline hospital leadership, he lays out a long-term vision that…

UAE Adeeb Al Attar leads Genpharm at a point where rare and advanced therapies in the Middle East face a more exacting test. Scale and ambition are no longer enough. What matters now is execution, credibility, and the ability to move innovation through complex healthcare systems without losing focus. In this…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Ribo Life Science raising over HKD 1.8 billion through its Hong Kong IPO, and Insilico Medicine signing a US$ 888 million AI-driven oncology collaboration with Servier. BioRay and Simcere Zaiming filed for Hong Kong IPOs to advance their pipelines,…

France A new chapter in vital organ care is unfolding as Vantive establishes its identity as an independent, purpose-driven leader in kidney care. With Trushar Patel stepping into an expanded leadership role across Europe, the company is accelerating efforts to transform dialysis through home-based therapies, digital innovation and deeper partnerships with…

France Kyowa Kirin’s new head for France and Benelux steps into the role at a time when rare diseases, regulatory expectations and scientific modalities are all shifting at speed. In this interview, Aurelie-Anne Chausse reflects on the recent strategic transition toward a fully rare-disease-focused organisation, the growing pressure to identify patients…

Taiwan Jayashri Kulkarni Managing Director of Johnson & Johnson Taiwan, brings 27 years of experience across pharmaceuticals and medical technology in Asia Pacific. Since assuming her Taiwan role , she has focused on outcome-based healthcare, patient advocacy, and leadership development, bringing a perspective that bridges emerging market innovation with healthcare system…

Taiwan With Takeda preparing for global leadership change and Taiwan rapidly upgrading its innovation and access frameworks, General Manager Alexis Lin is navigating one of the most pivotal periods in the affiliate’s 64-year history. Drawing on a career that began far from pharma, she has reshaped Takeda Taiwan into a regional…

USA Alberto Santagostino, CEO of AGC Biologics, discusses how the company is positioning itself in an increasingly regionalized CDMO market, the strategic value of its global manufacturing footprint, and the role of technical expertise and long-term partnerships in supporting advanced biologics and cell and gene therapy programs. Santagostino goes on to…

USA Loretta Beine, Senior Director of Industry Development for Life Sciences, Empire State Development (ESD) explains the organization’s broader role in growing New York State’s life sciences sector beyond direct funding. As New York State’s chief economic development agency, ESD focuses on supporting startups, attracting new investment, and job creation to…

Taiwan Nick Wang, General Manager of Daiichi Sankyo Taiwan, has more than 25 years’ experience across clinical research and commercial leadership. Since joining the company in 2020, he has led the build-out of its oncology business while steering the affiliate’s transition to a full-function organisation, with a clear focus on lifecycle…